Citizens JMP raised the firm’s price target on Sana Biotechnology (SANA) to $8 from $5 and keeps an Outperform rating on the shares. Sana’s enhanced Fusogen platform now offers improved specificity and expansion, with an IND filing anticipated in 2026, the analyst tells investors in a research note. Progress across multiple programs, including the modified pancreatic islet cell IST in T1D, the iPSC program nearing IND readiness, and SC291 data expected in 4Q25, combined with a $177.2M pro forma cash position, suggests the shares remain undervalued with potential upside from future Fusogen monetization, Citizens says.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SANA:
- Sana Biotechnology Advances CAR-T Therapy with SC262 in Non-Hodgkin’s Lymphoma Study
- Sana Biotechnology’s SC291 Study: A Promising Step in Autoimmune Disease Treatment
- Sana Biotechnology strength attributed to EMJ Capital long call
- Wedbush bullish on Sana Biotechnology, initiates with an Outperform
- Sana Biotechnology initiated with an Outperform at Wedbush